In a recent study published in the journal eLife, a team of researchers at Stanford University was able to identify a group of neurons that work together and fire in complex rhythms to send movement signals to muscles. “We hope to apply these findings to create prosthetic…

The ALS Association has recently awarded a $1.5 million grant to investigator Robert G. Miller, MD, to be invested in the study of a potential treatment for amyotrophic lateral sclerosis (ALS), called NP001. Dr. Miller is studying Neuraltus Pharmaceuticals’ investigational therapy which will now enter a phase 2 clinical trial.

Chris Rosati, who was diagnosed with amyotrophic lateral sclerosis (ALS) in November 2010, challenged the ALS Association to publicly declare that a cure for the disease will be found in the next six years. In an emotional video addressed to the association’s CEO Barbara Newhouse, Mr. Rosati explained…

The ALS Association participated in the annual BIO International Convention, which occured between June 15 and 18 in Philadelphia. Over 15,000 leaders from the pharmaceutical and biotech industries joined the convention which provided the association with crucial opportunities to establish partnerships that may further the development of treatments for amyotrophic lateral sclerosis disease (ALS). ALS is a…

Q Therapeutics, Inc., a clinical-stage company committed to find new therapies that might address central nervous system (CNS) diseases, has recently announced that the United States Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) so that Q-Cells’ Phase 1/2a trials can be initiated in patients with amyotrophic lateral sclerosis (ALS). ALS,…

Sigma-Aldrich Corporation recently announced it has established an agreement with XCell Science to launch genetically engineered human neural differentiated cells and the corresponding culture media to advance research in the neurological diseases field. Together with the product portfolio of Sigma-Aldrich, these new products offer unique tools relevant for the…

In a recent study published in the journal BMC Neurology researchers found that despite the lack of a curative therapy, Amyotrophic Lateral Sclerosis carergivers (including specialized physicians as well as nursing and familial caregivers) can substantially contribute to the maintenance of quality of life (QoL) at the…

Dr. Erik P. Pioro at the Neurological Institute, Cleveland Clinic in Ohio conducted a review on clinical data supporting treatment with dextromethorphan (DM) hydrobromide combined with quinidine sulfate (Q) for a disorder called pseudobulbar affect (PBA) that can occur in amyotrophic lateral sclerosis (ALS) patients. The study was published…

French pharmaceutical company AB Science SA has organized a web conference to present information on its lead product for the treatment of amyotrophic lateral sclerosis (ALS), a drug therapy called masitinib. The seminar held by AB Science, which is specialized in developing and commercializing protein…

The Annual Drug Company Working Group and the American Academy of Neurology (AAN) meetings were recently held by the ALS Association last month in Washington, D.C. with main focus on amyotrophic lateral sclerosis (ALS). The association is now sharing the most important data presented at the…